By using the Ladisch partitioning and microscale-analysis of HPTLC,the comparative quantitative and qualitative studies of gangliosides (Gg)and neutral glycosphingolipids(N-GSL)compositions from human chorionic villi ...By using the Ladisch partitioning and microscale-analysis of HPTLC,the comparative quantitative and qualitative studies of gangliosides (Gg)and neutral glycosphingolipids(N-GSL)compositions from human chorionic villi tissues of normal early pregnant women and women treated with mifepristone, norethisterone(NET)and tamoxifen(TAM)were reported in this paper.The patterns of Gg and N-GSL in three treated groups were similar to those in normal pregnant group.The total values of Gg from the chorionic villi tissues reduced significantly in three treated groups(P<0.01).In all treated groups,the amounts of NeuNAC-Gal-Glc-cer(GM3),NeuNAC-NeuNAC-Gal-Glc-cer(GD3)and Gal-GalNAC-(NeuNAC)-Gal-Glc-cer(GM1)were decreased significantly compared with those in normal(P<0.01orP<0.05).In NET and TAM groups,Neu NAC-Gal-GalNAC-(NeuNAC-NeuNAC)-Gal-Glc-cer(GT1b) was markedly lower than that in normal(P<0.01).The total values of N-GSL extracted from the chorionic villi tissues were obviously higher in mifepristone and TAM groups than those in normal(P<0.01).The Gal-Glc-cer(LacCer)(CDH)and Gal-Gal-Glc-cer(Gal-LacCer)(CTH)were greatly increased in mifepristone group as compared with normal P<0.05).Paragloboside:Gal-GalNAC-Gal-Glc-cer(PG)in NETgroup was significantly higher than that in normal(P<0.01).展开更多
目的探究人乳腺癌裸鼠移植动物模型体内孕激素受体膜组分1(PGRMC1)在黄体酮与炔诺酮(NET)刺激下对乳腺癌异种移植瘤增殖影响的差异性。方法构建PGRMC1稳定表达的人乳腺癌细胞系(MCF7),36只雌性BALB/c-nu裸鼠按随机数字表法分为MCF7/HA-P...目的探究人乳腺癌裸鼠移植动物模型体内孕激素受体膜组分1(PGRMC1)在黄体酮与炔诺酮(NET)刺激下对乳腺癌异种移植瘤增殖影响的差异性。方法构建PGRMC1稳定表达的人乳腺癌细胞系(MCF7),36只雌性BALB/c-nu裸鼠按随机数字表法分为MCF7/HA-PGRMC1组(n=18)和MCF7/HA-Vector组(n=18)。各鼠于颈部皮下包埋雌二醇(E_(2))缓释片。24 h后两组裸鼠左、右侧面皮下分别注射MCF7/HA-PGRMC1和MCF7/HA-Vector细胞悬液150μL,注射细胞数为1×107个。肿瘤生长至100 mm 3左右,将两组裸鼠进行组内分组,分别皮下联合包埋安慰剂、黄体酮缓释片、NET缓释片,即E_(2)+安慰剂亚组(n=6)、E_(2)+黄体酮亚组(n=6)、E_(2)+NET亚组(n=6)。记录肿瘤体积变化,绘制肿瘤生长曲线。45 d后完整摘除肿瘤组织免疫组化染色检测PGRMC1和Ki67表达情况。结果MCF7/HA-PGRMC1株系构建成功,在MCF7/HA-PGRMC1组中,与E_(2)+安慰剂亚组相比,E_(2)+黄体酮亚组肿瘤增长差异无统计学意义(P>0.05),而E_(2)+NET亚组肿瘤明显生长(P<0.05)。在MCF7/HA-Vector组中,与E_(2)+安慰剂亚组相比,E_(2)+NET亚组、E_(2)+黄体酮亚组的肿瘤增长差异均无统计学意义(P>0.05)。在MCF7/HA-PGRMC1组中,E_(2)+NET亚组Ki67呈强阳性表达,PGRMC1与Ki67表达呈正相关(r=0.892,P=0.014)。结论该实验在裸鼠体内证实PGRMC1过表达可特异性介导NET联合E_(2)的促乳腺癌增殖效应,而联合黄体酮并没有促进额外增殖。这一发现为临床激素治疗中孕激素类型的选择提供了关键的动物实验依据。展开更多
总结7种含有不同生物活性的常用甾体激素避孕药(Marvelon,Microgynon,中国Ⅰ号片,Mercilon,LNG事后药,Mesigyna,Cyclofem)对中国妇女脂代谢的影响。191例需要避孕的健康志愿者分别服用以上不同的避孕药,并依次在用药前、用药期间及停药...总结7种含有不同生物活性的常用甾体激素避孕药(Marvelon,Microgynon,中国Ⅰ号片,Mercilon,LNG事后药,Mesigyna,Cyclofem)对中国妇女脂代谢的影响。191例需要避孕的健康志愿者分别服用以上不同的避孕药,并依次在用药前、用药期间及停药后采空腹静脉血,观察血清中总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白-胆固醇(HDL-C)、低密度脂蛋白-胆固醇(LDL-C)、载脂蛋白A Ⅰ(apo A Ⅰ)、载脂蛋白AⅡ(apo AⅡ)、载脂蛋白B(apo B)水平变化及TC/HDL-C、apo A Ⅰ/apo B比值改变。共观察1665个周期。结果显示,以上7种避孕药均有升高或降低某些脂质水平的作用,但停药后均能恢复,而且无论在用药期间或停药后,以上两项比值无显著改变。结果提示短期服用以上7种避孕药(一年内),对脂代谢无不良影响,并发现由于各种甾体激素类避孕药的配伍各异,因而产生的生物活性不同,对人体脂代谢的影响亦不一致。因此建议如能交替使用不同种类的避孕药,也许可减少长期服药者副作用的发生。展开更多
文摘By using the Ladisch partitioning and microscale-analysis of HPTLC,the comparative quantitative and qualitative studies of gangliosides (Gg)and neutral glycosphingolipids(N-GSL)compositions from human chorionic villi tissues of normal early pregnant women and women treated with mifepristone, norethisterone(NET)and tamoxifen(TAM)were reported in this paper.The patterns of Gg and N-GSL in three treated groups were similar to those in normal pregnant group.The total values of Gg from the chorionic villi tissues reduced significantly in three treated groups(P<0.01).In all treated groups,the amounts of NeuNAC-Gal-Glc-cer(GM3),NeuNAC-NeuNAC-Gal-Glc-cer(GD3)and Gal-GalNAC-(NeuNAC)-Gal-Glc-cer(GM1)were decreased significantly compared with those in normal(P<0.01orP<0.05).In NET and TAM groups,Neu NAC-Gal-GalNAC-(NeuNAC-NeuNAC)-Gal-Glc-cer(GT1b) was markedly lower than that in normal(P<0.01).The total values of N-GSL extracted from the chorionic villi tissues were obviously higher in mifepristone and TAM groups than those in normal(P<0.01).The Gal-Glc-cer(LacCer)(CDH)and Gal-Gal-Glc-cer(Gal-LacCer)(CTH)were greatly increased in mifepristone group as compared with normal P<0.05).Paragloboside:Gal-GalNAC-Gal-Glc-cer(PG)in NETgroup was significantly higher than that in normal(P<0.01).
文摘目的探究人乳腺癌裸鼠移植动物模型体内孕激素受体膜组分1(PGRMC1)在黄体酮与炔诺酮(NET)刺激下对乳腺癌异种移植瘤增殖影响的差异性。方法构建PGRMC1稳定表达的人乳腺癌细胞系(MCF7),36只雌性BALB/c-nu裸鼠按随机数字表法分为MCF7/HA-PGRMC1组(n=18)和MCF7/HA-Vector组(n=18)。各鼠于颈部皮下包埋雌二醇(E_(2))缓释片。24 h后两组裸鼠左、右侧面皮下分别注射MCF7/HA-PGRMC1和MCF7/HA-Vector细胞悬液150μL,注射细胞数为1×107个。肿瘤生长至100 mm 3左右,将两组裸鼠进行组内分组,分别皮下联合包埋安慰剂、黄体酮缓释片、NET缓释片,即E_(2)+安慰剂亚组(n=6)、E_(2)+黄体酮亚组(n=6)、E_(2)+NET亚组(n=6)。记录肿瘤体积变化,绘制肿瘤生长曲线。45 d后完整摘除肿瘤组织免疫组化染色检测PGRMC1和Ki67表达情况。结果MCF7/HA-PGRMC1株系构建成功,在MCF7/HA-PGRMC1组中,与E_(2)+安慰剂亚组相比,E_(2)+黄体酮亚组肿瘤增长差异无统计学意义(P>0.05),而E_(2)+NET亚组肿瘤明显生长(P<0.05)。在MCF7/HA-Vector组中,与E_(2)+安慰剂亚组相比,E_(2)+NET亚组、E_(2)+黄体酮亚组的肿瘤增长差异均无统计学意义(P>0.05)。在MCF7/HA-PGRMC1组中,E_(2)+NET亚组Ki67呈强阳性表达,PGRMC1与Ki67表达呈正相关(r=0.892,P=0.014)。结论该实验在裸鼠体内证实PGRMC1过表达可特异性介导NET联合E_(2)的促乳腺癌增殖效应,而联合黄体酮并没有促进额外增殖。这一发现为临床激素治疗中孕激素类型的选择提供了关键的动物实验依据。
文摘总结7种含有不同生物活性的常用甾体激素避孕药(Marvelon,Microgynon,中国Ⅰ号片,Mercilon,LNG事后药,Mesigyna,Cyclofem)对中国妇女脂代谢的影响。191例需要避孕的健康志愿者分别服用以上不同的避孕药,并依次在用药前、用药期间及停药后采空腹静脉血,观察血清中总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白-胆固醇(HDL-C)、低密度脂蛋白-胆固醇(LDL-C)、载脂蛋白A Ⅰ(apo A Ⅰ)、载脂蛋白AⅡ(apo AⅡ)、载脂蛋白B(apo B)水平变化及TC/HDL-C、apo A Ⅰ/apo B比值改变。共观察1665个周期。结果显示,以上7种避孕药均有升高或降低某些脂质水平的作用,但停药后均能恢复,而且无论在用药期间或停药后,以上两项比值无显著改变。结果提示短期服用以上7种避孕药(一年内),对脂代谢无不良影响,并发现由于各种甾体激素类避孕药的配伍各异,因而产生的生物活性不同,对人体脂代谢的影响亦不一致。因此建议如能交替使用不同种类的避孕药,也许可减少长期服药者副作用的发生。
